男性乳腺癌虽然罕见，但已成为一个相关的公共卫生问题，比女性患者具有25%更高的死亡风险。在临床试验中，男性的代表性很少，治疗决策主要基于女性数据的推断。在雌激素依赖的转移性疾病的情况下，依维莫司的使用很少被报道，尽管PI3K/AKT/mTOR途径似乎是一个关键的致癌驱动因素。本文对雌激素受体阳性/HER2阴性男性乳腺癌的显著生物特征进行了剖析，并为推动个体化护理提供了全面的基础，重点关注靶向PI3K/AKT/mTOR途径的潜力。版权所有 © 2023，Elsevier Ltd.已发表。

Breast cancer in men is rare, but a relevant public health issue, yielding a 25% higher risk of mortality comparing to female counterparts. The representation of males in clinical trials has been scarce and treatment decisions are based mainly on extrapolations from data in females. In the setting of estrogen-dependent metastatic disease, the use of everolimus has been seldom reported, although the PI3K/AKT/mTOR pathway seems to be a critical oncogenic driver. This paper dissects hallmark biological features of ER+/HER2-advanced male breast cancer, setting a comprehensive basis to promote personalized care, focusing on the potential of targeting the PI3K/AKT/mTOR pathway.Copyright © 2023. Published by Elsevier Ltd.